Preferentially Expressed Antigen in Melanoma (PRAME) may be well suited for TCR-T therapy of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) through its broad overexpression in leukemic blasts of myeloid origin. Here, PRAME is linked to myelodysplastic syndrome.